The effect of neuropalliative care on quality of life and satisfaction with quality of care in patients with progressive neurological disease and their family caregivers: an interventional control study

Radka Bužgová1*, Radka Kozáková1 and Michal Bar2

Abstract

Background: It is recommended that patients with progressive neurological disease (PND) receive general and specialized palliative care. The purpose of this study was to determine the effect of neuropalliative care on quality of life (QoL) and satisfaction with provided care in both patients with PND in advanced stages of disease and their family caregivers.

Methods: The sample consisted of 151 patients with PND and 140 family caregivers. The PNDQoL questionnaire was used for data collection. Patients and family caregivers completed the questionnaires both before and 3 months after the intervention.

Results: Before intervention, there were no statistically significant differences in the individual domains of QoL in patients and family caregivers in either the intervention or the control group. After intervention, differences were identified in the sample of patients in the domains of symptoms burden \( (p < 0.001) \), emotional \( (p < 0.001) \), social functioning \( (p = 0.046) \), spiritual area (nonreligious) \( (p = 0.050) \), and in QoL. In the sample of family caregivers, there were differences in the domains of symptoms burden \( (p < 0.001) \), emotional functioning \( (p = 0.016) \), spiritual area (nonreligious) \( (p = 0.042) \), and in the assessment of health \( (p = 0.002) \), and QoL \( (p = 0.002) \). Patients and family caregivers from the intervention group evaluated their satisfaction with the quality of care provided significantly more positively in all five analyzed domains.

Conclusion: The provision of neuropalliative care to patients with advanced stages of PND helped to maintain and slightly improve their QoL, and symptoms burden, and resulted in a more positive assessment of satisfaction with the quality of care provided.

Keywords: Quality of life, Palliative care, Symptoms burden, Subjective assessment
Background
Despite developments in scientific knowledge in the fields of neurology and molecular biology, and significant progress in the treatment of patients with progressive neurological disease (PND), there are still many treatment procedures, especially for patients with motor neuron disease (MND), Parkinson’s disease (PD), multiple sclerosis (MS), or other neurodegenerative diseases, that are palliative, rather than curative. Such treatment focuses on the reduction of symptoms, improving quality of life, and, in some cases, prolongation of the patient’s life [1]. The concept of neuropalliative and rehabilitative care suitable for patients with PND is defined by Sutton [2] as “a holistic approach to the care of neurological patients with significant disability, complex needs, and a potentially shortened life-span. It is patient-centered and involves diagnosis of clinical problems at all stages, rehabilitation to maintain function, care coordination and appropriate palliation to relieve symptoms”. Recently, an increasing number of authors have focused on the integration of palliative care into neurology [3–6].

The European Federation of Neurological Societies (EFNS) in its key neurological guidelines also recommends that all patients with PND are provided with multidisciplinary care, and have access to both general and specialized palliative care [7].

For neurological patients, the most appropriate forms appear to be what are known as “early” palliative care and the “dynamic model” of palliative care [8, 9]. Early palliative care does not exclude the concurrence of curative and palliative care, the intensity of palliative care services gradually increasing as the disease advances. In the dynamic model, specialized palliative care services are provided based on trigger points, i.e., at intermittent periods according to the patients’ needs [8, 10]. The aim of palliative care in all stages of disease should be to achieve the optimum quality of life for patients and their families [11, 12]. On the other hand, specialized palliative care should be provided in the form of complex interventions which positively impact the QoL of patients and their family members, reduce the burden of physical symptoms, and have a positive effect on psychosocial and spiritual issues, individual preference of care, and the quality of death and dying [9]. Analysis of patients’ subjective perception of the impact of disease and treatment on activities of daily living, ability to self-care, emotional experiences, social relationships, and level of anxiety, tension, and depression is very important for the evaluation of the quality of care provided to patients with PND.

Based on a systematic review and meta-analysis, Kavalieratos et al. [13] found that palliative care intervention (e.g. symptom management, communication and goal setting, carer support, end of life care) is associated with improved quality of life of patients with life-limiting disease, and a mitigated symptoms burden. However, they did not find any connection between palliative care and survival. Few studies have been published analyzing the positive effects of neuropalliative care on the quality of life of patients with PND and their family caregivers, or on satisfaction with provided care. Several studies have indicated improved quality of life, and reduced pain, dyspnea, sleep disorders, and bowel symptoms, after the application of palliative care to patients with amyotrophic lateral sclerosis [14, 15], multiple sclerosis [16], Parkinson’s disease [17], neurodegenerative diseases [18]; and, in addition, a reduced burden for family caregivers [16]. A randomized study confirmed the financial efficiency of early palliative care in patients with multiple sclerosis [19]. Oliver and Veronese [9] recommend further research to focus on the effect of complex specialized palliative care interventions on all aspects of quality of life of patients with PND.

There is also a lack of studies confirming the satisfaction of neurological patients and their family caregivers with the palliative care interventions provided. In terms of palliative care, only the satisfaction of oncological patients has been assessed in a study [20–25].

The aim or our research was to analyze the effect of neuropalliative care of patients with PND in advanced stage of disease (PPS - Palliative Performance Scale ≤70 points) and their family caregivers on their quality of life and their satisfaction with the care provided. Another aim was to determine predictors of change in quality of life of patients and their family caregivers.

Methods
Design
We performed an interventional study – randomized controlled trial study design. Intervventional study is specifically tailored to evaluate direct impacts of treatment measures on disease. Randomized controlled trials are the most common type of interventional study [26].

Participants
The sample included 291 participants (151 patients with PND and 140 family caregivers) who met the following criteria:

- Sample of patients with PND: diagnosed with selected PNDs according to ICD-10: multiple sclerosis (G-35), Parkinson’s disease (G-20), motor neuron disease (G-12.2); aged 18+ years; PPS (Palliative Performance Scale) ≤ 70 points; MMSE (Mini-Mental State Examination) ≥ 24 points; and consenting to participation by signed informed consent.
Patients with PND and their family caregivers were recruited via four institutions in the Moravian-Silesian region of the Czech Republic: 1. the Neurology Department of University Hospital, Ostrava (the Therapeutic Center for Demyelination Diseases and the outpatient department for extrapyramidal diseases and cognitive disorders); 2. Chuchelná Rehabilitation Institute; 3. social institutional care (residential care home for the elderly); and 4. a nursing home in Ostrava. A doctor or head nurse from each facility selected all suitable patients with PND, based on the stated criteria, who were then invited to join the study. Having consented to participation, the patients with PND were then placed randomly either in the intervention group or in the control group, according to the final digit in their social security number – National ID number (odd/even). Categorization was performed by a doctor or the study coordinator. Afterwards, family caregivers were also invited to participate, and were placed in the same group as their patients (intervention/control group). Eleven family caregivers chose not to participate in the project. They don’t agree with participation because they didn’t want to fill the questionnaires.

**Intervention**

The research involved an interventional control study. The intervention consisted of neuropalliative care in the form of multidisciplinary palliative team consultations. A four doctors (neurologist) evaluated the functional scales (EDSS – Expanded Disability Status scale [27] for multiple sclerosis patients; ALS function rating scale for patients with amyotrophic lateral sclerosis [28]; Schwab and England Activities of Daily Living scale for patients with Parkinson’s disease [29]; while the PPS (Palliative Performance Scale) [30] and ADL (Activities of Daily Living) [31] were evaluated for all patients. The doctors were not part of the multidisciplinary care team.

Patients with PND and family caregivers were asked to complete a quality of life evaluation questionnaire (Time I). Then the study coordinator contacted the patients from the intervention group to offer them a consultation with a multidisciplinary palliative team (doctor – palliative care physician, nurse, social workers, psychologist, priest, physiotherapist, speech therapist, and occupational therapist). Based on the patient’s needs, the intervention was provided in the form of individual consultations with a specific expert, in which family caregivers could also participate. The duration of a consultation was 45–60 min. The consultations were provided in the outpatients’ department, in the facility or the home of the client. The doctor’s consultations were focused on mitigating the symptoms (pain, other symptoms causing suffering) and dealing with the patient’s discomfort including medication adjustments, formulating a plan of care, and objectives of treatment during the individual stages of the disease.

The physiotherapist and the occupational therapist discussed the functional objectives (self-care, limits to self-sufficiency), respiratory and cognitive rehabilitation, care focusing on spasticity and mobility, timely provision of proper equipment. The speech therapist recommended care focusing on the option of alternative communication in case of speech difficulties. The psychologist offered help with the adaptation to the disease, managing one’s emotions, social changes, and the increased dependency on the help of others, including the support of maintaining one’s dignity. Furthermore, the psychologist focused on the connection between the physical symptoms and the mental state of the patient. The social worker discussed the options of financial support and securing the social services. The team members were not from some health care facilities. The team coordinated the study coordinator, and the professional communicated with each other by phone. The average number of professionals who consulted with one patient and their family caregivers was 3.4.

The control group patients were provided with standard care. Standard care included routine care by a neurologist (routine visit in an outpatient setting or institutional care). The neurologist consulted symptoms and prescribed medication. The nursing assistant care was provided to patients who lived in a nursing home or social institutional care. In these facilities, the standard care was provided by a neurologist who visited the facility externally.

After 3 months, the patients with PND and family caregivers were asked again to complete the quality of life evaluation questionnaire and a questionnaire analyzing their satisfaction with provided care (Time II). A paper-and-pencil version of the questionnaires could be completed in the facilities or taken home and returned in person or by mail.

The patients in the control group could consult with a multidisciplinary palliative team after the study.

**Data collection**

**Quality of life** was measured with the PNDQoL [32] questionnaire (Progressive Neurological Diseases Quality of Life), with versions for patients and family caregivers. It was developed and validated in our research project. We created a questionnaire specifically for patients with PND and their caregivers in Czech version, which would reflect the specific problems of these patients and their family caregivers in the context of the Czech
environment. Appropriate psychometric characteristics were verified. Acceptable reliability was found in all domains of the questionnaire for patients with PND ($\alpha = 0.727–0.834$) and family caregivers ($\alpha = 0.735–0.923$), [32].

The PNDQoL includes symptomatic and functional scales, and assessment of global health and global QoL.

The symptomatic scale for patients asks them to rate 11 symptoms (pain, fatigue, sleepiness, dyspnea, tremor, stiffness, spasms, swallowing, salivation, excretion, and urination) from 0 (none) to 10 (severe); while the version for family caregivers asks them to rate ten physical symptoms (pain, tiredness, sleep dysfunctions, pounding heart, dyspnea, problems with food intake, nausea, skin problems, sexual problems, and excretory problems) from 0 (none) to 4 (very many). The overall scores for the two symptomatic scales can range from 0 to 110 points (patients) and from 0 to 40 points (family caregivers). The higher the number of points, the greater the burden of symptoms.

The functional scale of QoL (32 items) is divided into four domains: 1. activities of daily living, 2. emotional functioning, 3. social functioning, and 4. spiritual areas, with each domain containing eight items. The items are evaluated on a 5-point Likert scale ranging from 0 (not at all) to 5 (totally satisfied). Using Cronbach’s alpha ($\alpha = 0.830–0.914$; family caregivers’ domains: $\alpha = 0.863–0.939$).

Data analysis
The normality of data distribution was tested by means of the Shapiro-Wilk test. The data are depicted through descriptive statistics – mean, standard deviation, and relative and absolute frequency. To evaluate the differences between the groups, the non-parametric Wilcoxon two-sample test for independent samples (Mann-Whitney U test), and Wilcoxon signed-rank test were used. The predictors influencing changes in QoL were tested through multiple linear regression analysis. The following are the predictor variables for patients: palliative intervention, gender, age, marital status, and PPS score; and for family caregivers: intervention, gender, age, marital status, and patients’ PPS score. The statistical significance was tested with the significance level $p < 0.05$. The data were analyzed using the software SPSS v. 24.0 (IBM, Armonk, NY, USA).

Results
Sociodemographic characteristics of the sample
A total of 151 patients with PND (98 in the intervention group, and 53 in the control group) and 140 family caregivers (93 in the intervention group, and 47 in the control group) participated in the study. The family caregivers were most often the life partners of the patients (intervention: 43%, control: 55.3%), their children (intervention: 36.6%, control: 29.8%), parents (intervention: 11.8%, control: 12.8%), or other relatives (intervention: 8.6%, control 2.1%). The sociographic characteristics of the sample are depicted in Table 1.

Evaluation of the difference in quality of life between the intervention and control groups
First, we assessed the difference between the intervention and control groups during the first and second measurements (see Table 2). Before the intervention (Time I), no statistically significant differences were found in the evaluation of the individual domains of the quality of life of the patients with PND and family caregivers included in the intervention and control samples. In the second measurement (Time II), a statistically significant difference in certain parameters was found in the sample of patients. Following intervention, patients from the intervention group had a lower symptoms burden ($p < 0.001$), and a more positive evaluation of emotional functioning ($p < 0.001$), social functioning ($p = 0.046$), spiritual area (nonreligious) ($p = 0.050$), and global QoL ($p = 0.023$). Similarly, the family caregivers from the intervention group had a lower symptoms burden ($p < 0.001$), better emotional functioning ($p = 0.016$), and spiritual area (nonreligious) ($p = 0.042$), and a more
positive evaluation of global QoL ($p = 0.001$) and global health ($p = 0.002$).

**Evaluation of the difference in quality of life between first and second measurements**

Differences between the first and second measurements were assessed in the intervention and control groups (see Table 3). The patients and the family caregivers from the intervention group scored lower (had better quality of life) on the symptomatic scale ($p < 0.001$) and in all domains of the functional scale except the spiritual area/religious domain. After intervention (Time II) patients and family caregivers evaluated global quality of life ($p < 0.001$) and global health ($p < 0.001$) more positively. On the other hand, the patients and family caregivers from the control sample did not demonstrate any statistically significant changes.

**Evaluation of predictors of change in quality of life**

The results of the linear regression analysis can be found in Table 4. Only domains in which the model was statistically significant are depicted. In all QoL domains, the predictor of change was confirmed to be the provided intervention. Furthermore, in certain domains, gender

---

**Table 1 Sociodemographic characteristics of the sample**

|                      | Patients with PND | Family caregivers |
|----------------------|-------------------|-------------------|
|                      | interventional $N = 98$ | control $N = 53$ | total $N = 151$ | interventional $N = 93$ | control $N = 47$ | total $N = 140$ |
| **Age** N (%)        |                   |                   |                   |                   |                   |                   |
| mean (SD)            | 62.6 (13.4)       | 66.3 (11.5)       | 63.9 (12.8)       | 52.7 (14.9)       | 58.1 (14.4)       | 54.5 (14.9)       |
| Min–max              | 38–90             | 43–91             | 38–91             | 22–84             | 26–85             | 22–85             |
| **Gender** N (%)     |                   |                   |                   |                   |                   |                   |
| Man                  | 39 (39.8)         | 22 (41.5)         | 61 (40.4)         | 38 (41.3)         | 17 (36.2)         | 55 (39.6)         |
| Women                | 59 (60.2)         | 31 (58.8)         | 90 (59.6)         | 55 (58.7)         | 30 (63.8)         | 85 (60.4)         |
| **Marital status** N (%) |               |                   |                   |                   |                   |                   |
| Single               | 11 (11.2)         | 3 (5.7)           | 14 (9.3)          | 18 (19.6)         | 6 (12.8)          | 24 (17.3)         |
| Married              | 48 (49.0)         | 31 (58.5)         | 79 (52.3)         | 67 (71.7)         | 33 (70.2)         | 100 (71.2)        |
| Divorced             | 20 (20.4)         | 6 (11.3)          | 26 (17.2)         | 6 (6.5)           | 7 (14.9)          | 13 (9.4)          |
| Widow/er             | 19 (19.4)         | 13 (24.5)         | 32 (21.2)         | 2 (2.2)           | 1 (2.1)           | 3 (2.2)           |
| **Education** N (%)  |                   |                   |                   |                   |                   |                   |
| Elementary           | 17 (17.3)         | 11 (20.8)         | 28 (18.5)         | 4 (4.3)           | 10 (21.3)         | 14 (10.0)         |
| Secondary            | 69 (70.4)         | 38 (71.6)         | 107 (70.8)        | 62 (66.6)         | 28 (59.6)         | 90 (64.3)         |
| Higher               | 3 (3.1)           | 0 (0.0)           | 3 (2.0)           | 15 (16.1)         | 5 (10.6)          | 20 (14.3)         |
| Tertiary             | 9 (9.2)           | 4 (7.5)           | 13 (8.6)          | 12 (12.9)         | 4 (8.5)           | 16 (11.4)         |
| **Employment** N (%) |                   |                   |                   |                   |                   |                   |
| Employee             | 3 (3.1)           | 2 (3.8)           | 5 (3.3)           | 58 (62.4)         | 20 (41.3)         | 78 (55.7)         |
| Unemployed           | 0 (0.0)           | 0 (0.0)           | 0 (0.0)           | 1 (1.1)           | 2 (4.3)           | 3 (2.1)           |
| Invalid pensioner    | 48 (49.0)         | 21 (39.6)         | 69 (45.7)         | 2 (2.2)           | 3 (6.5)           | 5 (3.6)           |
| Old-age pensioner    | 47 (48.0)         | 30 (56.6)         | 77 (51.0)         | 3 (3.2)           | 18 (39.1)         | 21 (15.0)         |
| Other                | 0 (0.0)           | 0 (0.0)           | 0 (0.0)           | 29 (31.1)         | 4 (6.5)           | 33 (23.6)         |
| **Children** N (%)   |                   |                   |                   |                   |                   |                   |
| Yes                  | 84 (85.7)         | 48 (90.6)         | 132 (87.4)        | 74 (79.6)         | 41 (87.2)         | 115 (82.1)        |
| **Length of diseases/care** |           |                   |                   |                   |                   |                   |
| Mean (SD)            | 164 (11.6)        | 10.1 (7.7)        | 141 (10.8)        | 10.2 (8.8)        | 7.33 (8.5)        | 9.21 (8.7)        |
| Min–max              | 2–37 years        | 2–30 years        | 2–37 years        | 1–25 years        | 0–22 years        | 0–25 years        |
| **Disease**          |                   |                   |                   |                   |                   |                   |
| Multiple sclerosis    | 54 (55.1)         | 34 (64.2)         | 88 (58.3)         | 51 (54.8)         | 31 (65.9)         | 82 (58.7)         |
| Parkinson’s           | 42 (42.9)         | 16 (30.2)         | 58 (38.4)         | 40 (43.0)         | 13 (27.7)         | 53 (37.6)         |
| Motor neuron          | 2 (2.0)           | 3 (5.6)           | 5 (3.3)           | 2 (2.2)           | 3 (6.4)           | 5 (3.7)           |
### Table 2  
**Comparison of differences regarding evaluation of individual quality of life domains of patients and family caregivers in intervention and control samples during first and second measurements**

|                      | Patients with PND |                      | Family caregivers |
|----------------------|-------------------|----------------------|------------------|
|                      | Interven. N = 98  | Control N = 53       |                  |
|                      | Time I x̄ (s)     | Time II x̄ (s)       | N = 93 (N = 47)  |
| Symptoms burden      | 41.2 (16.2)       | 43.4 (16.2)          | 8.8 (7.7)        |
|                      | 2.2 0.287         | 4.63 (18.3)          | 9.4 (6.4)        |
| Activities of daily living | 52.6 (21.9)     | 52.2 (21.9)          | 34.5 (25.6)      |
|                      | −0.4 0.925        | 51.7 (23.1)          | −7.4 0.106       |
| Emotional functioning | 40.9 (19.4)       | 43.3 (16.7)          | 31.6 (24.3)      |
|                      | 2.4 0.282         | 33.9 (19.2)          | −6.1 0.201       |
| Social functioning   | 47.1 (17.1)       | 47.8 (16.8)          | 40.5 (14.7)      |
|                      | 0.7 0.874         | 43.5 (14.7)          | −5.1 0.061       |
| Spiritual (nonreligious) | 50.2 (18.1)    | 51.8 (19.0)          | 30.8 (17.6)      |
|                      | 1.6 0.873         | 46.6 (19.1)          | −3.6 0.001       |
| Spiritual (religious) | 42.2 (15.6)      | 43.2 (13.9)          | 40.0 (18.1)      |
|                      | 1.0 0.905         | 42.8 (14.6)          | −0.5 0.107       |
| Global QoL           | 4.5 (1.6)         | 4.4 (1.6)            | 6.7 (2.3)        |
|                      | 0.3 0.351         | 5.3 (1.7)            | 6.2 (2.2)        |
| Global health        | 4.2 (1.5)         | 4.5 (1.7)            | 6.9 (2.3)        |
|                      | 0.3 0.351         | 4.9 (1.5)            | −0.7 0.063       |

* Table 2: Comparison of differences regarding evaluation of individual quality of life domains of patients and family caregivers in intervention and control samples during first and second measurements.

---

### Table 3  
**Comparison of differences regarding evaluation of QoL domains by patients and family caregivers in intervention and control samples during first and second measurements**

|                      | Interventional |                      | Control |
|----------------------|----------------|----------------------|---------|
|                      | Time I x̄ (s)  | Time II x̄ (s)       | Diff. x | P*     |
| Symptoms burden      | 41.2 (16.2)    | 35.8 (15.7)          | −5.4    | < 0.001|
|                      | 43.4 (16.2)    | 46.3 (18.3)          | 2.9     | 0.125  |
| Activities of daily living | 52.6 (21.9)   | 50.0 (19.9)          | −2.6    | 0.021  |
|                      | 52.2 (21.9)    | 51.7 (23.1)          | −0.6    | 0.837  |
| Emotional functioning | 40.9 (19.4)    | 33.9 (19.2)          | −7.0    | < 0.001|
|                      | 43.3 (16.7)    | 43.9 (17.7)          | 0.6     | 0.747  |
| Social functioning   | 47.1 (17.1)    | 43.5 (14.7)          | −3.6    | < 0.001|
|                      | 47.8 (16.8)    | 50.1 (17.3)          | 2.3     | 0.159  |
| Spiritual (nonreligious) | 50.2 (18.1)   | 46.6 (19.1)          | −3.6    | 0.001  |
|                      | 51.8 (19.0)    | 53.7 (19.2)          | 1.9     | 0.178  |
| Spiritual (religious) | 42.2 (15.6)    | 42.8 (14.6)          | 0.6     | 0.260  |
|                      | 43.2 (13.9)    | 45.3 (15.1)          | 2.1     | 0.112  |
| Global QoL           | 4.5 (1.6)      | 5.3 (1.7)            | 0.8     | < 0.001|
|                      | 4.4 (1.6)      | 4.6 (1.9)            | 0.2     | 0.457  |
| Global health        | 4.2 (1.5)      | 4.9 (1.5)            | 0.7     | < 0.001|
|                      | 4.5 (1.7)      | 4.7 (1.8)            | 0.2     | 0.303  |

* Table 3: Comparison of differences regarding evaluation of QoL domains by patients and family caregivers in intervention and control samples during first and second measurements.

---

*Mann-Whitney U test

*Wilcoxon signed-rank test
and marital status (patients’ sample), and marital status and patients’ PPS score (family caregivers sample) were additional predictors of change.

**Evaluation of differences regarding satisfaction with provided care**
When assessing their satisfaction with the provided care, patients with PND and family caregivers from the intervention group reported significantly higher satisfaction with the provided care in all evaluated areas (see Table 5).

**Discussion**
Palliative care in neurology has been a focus of discussion in recent years [4–9]. Applying general and specialized palliative care to patients with PND may benefit both the patients [14–18] and their family caregivers [16]. Specialized palliative care offers the possibility of consultations with a palliative team. In our study, we analyzed the benefits of consultations with a multidisciplinary team in connection with QoL and satisfaction with care in patients with PND and their family caregivers. Multidisciplinary team consultations were provided in the care facilities of the patients with PND. Evaluating the efficacy of palliative services and programs is one of the priorities of current international research regarding palliative care [24] of patients with PND and other diseases. There are two major reasons for the assessment of quality of life in research and clinical practice within palliative care. First, quality of life is an input variable of the level of impact of certain diseases and their treatment on the life of patients, and, second, it is an output variable representing the level of success of certain interventions [34]. In our study, we viewed the evaluation of quality of life as an output variable; thus reflecting the level of success of the provided intervention – i.e., consultations with the multidisciplinary palliative care team. In our sample, patients in advanced stages of disease were included (Palliative Performance Scale ≤ 70), i.e., when their disease had significantly limited their mobility, ability to work or activities at home, and substantial symptoms had manifested themselves.

### Table 4 Predictors of change in individual quality of life domains

| Independent variables | Total QoL | Total health | D2 | D3 | D4a |
|-----------------------|----------|--------------|----|----|-----|
| PATIENTS              | β        | p            | β  | p  | β   |
| Intervention          | −0.194   | 0.025        | −0.199 | 0.020 | 0.273 |
| Gender                | 0.212    | 0.016        | 0.226 | 0.009 | −0.068 |
| Age                   | −0.075   | 0.386        | −0.060 | 0.485 | 0.007 |
| Marital status        | 0.111    | 0.620        | 0.193 | 0.024 | −0.197 |
| PPS                   | 0.043    | 0.198        | 0.037 | 0.663 | 0.018 |
| Model sum.            | 0.026    | 0.007        | 0.014 | 0.001 | 0.004 |

| FAMILY CAREGIVERS     | β        | p            | β  | p  | β   |
|-----------------------|----------|--------------|----|----|-----|
| Intervention          | 0.254    | 0.048        | 0.282 | 0.041 | −0.249 |
| Gender                | 0.013    | 0.876        | 0.025 | 0.777 | 0.113 |
| Age                   | 0.116    | 0.213        | 0.151 | 0.122 | −0.171 |
| Marital status        | −0.267   | 0.005        | −0.250 | 0.011 | 0.344 |
| Patients PPS          | 0.269    | 0.002        | 0.075 | 0.389 | −0.213 |
| Model sum.            | 0.001    | 0.048        | 0.000 | 0.001 | 0.040 |

D2 – emotional functioning, D3 – social functioning, D4a – spiritual area (nonreligious)

### Table 5 Comparison of satisfaction-with-care evaluation of intervention and control groups

| Satisfaction with care | Patients with PND | Family caregivers |
|------------------------|-------------------|-------------------|
|                        | Intervention | Control | Difference | p* | Intervention | Control | Difference | p* |
| 1_ Overall satisfaction| 86.8 (14.8) | 80.0 (15.8) | −6.8 | 0.009 | 88.5 (14.6) | 80.5 (20.2) | −8.0 | 0.025 |
| 2_ Relation to doctor | 87.3 (13.2) | 79.8 (14.6) | −7.5 | 0.002 | 86.5 (13.6) | 78.8 (20.7) | −7.7 | 0.040 |
| 3_ Health worker care | 85.9 (13.6) | 79.7 (14.9) | −6.2 | 0.020 | 88.1 (13.3) | 81.3 (18.3) | −6.8 | 0.053 |
| 4_ Disease management| 59.7 (23.9) | 52.8 (20.9) | −6.9 | 0.045 | 87.7 (12.8) | 79.5 (17.0) | −8.2 | 0.009 |
| 5_ Communication/decisions | 85.6 (14.5) | 77.9 (14.7) | −7.7 | 0.002 | 87.3 (13.3) | 79.5 (14.2) | −7.8 | 0.002 |
were not in terminal stages of disease, they could be provided with early palliative care, as recommended for patients with PND [6, 35], to improve symptom management and the well-being of patients and their families [16, 19].

**Main findings**

The most significant finding of our research is the confirmation of the positive effect of the intervention (i.e., consultations with the neuropalliative multidisciplinary team) provided to patients with PND and their family caregivers on quality of life in almost all areas. Consultations with a multidisciplinary palliative team may help patients with PND to change their subjective view of quality of life in a positive way. Mitigating the symptoms burden, changing the importance of quality of life domains, and changing the perception of the control patients have over certain areas of their quality of life, or, alternatively, learning to accept and live with reduced quality of life, may help patients evaluate subjective quality of life more positively [36]. These topics may be discussed by patients and family caregivers, within the psychosocially supportive environment provided by the multidisciplinary team.

On the other hand, no association was found between the provided intervention and spiritual area (religious). Neither patients with PND nor family caregivers wished to discuss this area during consultations with the multidisciplinary team. An improvement was identified in the non-religious area, which included evaluation of the degree of meaningfulness of life, composure, control over one’s own life, and desperation. 31 This may be due to the fact that the Czech Republic is largely an atheist country [36], in which non-religious topics may be more commonly discussed as part of spiritual care. A connection between palliative care and spirituality has been confirmed in a number of studies [37].

We also studied the predictors of change in quality of life. The provided intervention was confirmed as a predictor, and in some domains, gender (global health, global QoL) and marital status (emotional functioning, global health, spiritual area (nonreligious)) were also predictors. While the functional state of the patients, determined through the PPS scale, was not confirmed as a predictor for patients, it was confirmed as such for family caregivers. A worse functional state in patients represented a greater burden for family caregivers.

Another important finding of our research is the fact that neuropalliative care improves satisfaction with provided care for both patients with PND and their family caregivers. A significant difference in evaluation was determined in the domain “disease management”, in which patients and the family caregivers were asked questions regarding their satisfaction with the treatment, resolution of physical and emotional problems, and succession of care, and services provided in the household of the patient. A multidisciplinary approach may help patients resolve not only the physical problems resulting from the disease but also any emotional issues, and it may help secure successive health/social care based on the individual needs of the client [1]. However, on the basis of a literature overview, Aspiral et al. [25] warn that using satisfaction as a method of evaluating the quality of health services can be problematic. One of the reasons is that satisfaction is under-theorized and no widely accepted definition exists. However, satisfaction with care can be important for the quality of life of patients and their family caregivers. That is the reason why is appropriate to measure it.

An important recommendation of our research is that neuropalliative care should be used for patients with PND before they reach the terminal stage of the disease.

**Limitations**

A limitation of the study was the uneven number of respondents in the intervention and control groups, caused by random categorization of patients according to the last digit of their social security number. This was intended to prevent patients more likely to improve after intervention from deliberately being included in the intervention group.

Other limitations of the study were the low number of patients with MND, due to the unwillingness of MND patients to participate in the research and inclusion criterion for patients PPS ≤70. Our study aimed to analyze the effect of neuropalliative care of patients with PND in the advanced stage of the disease. The patients with PPS = 70 points are questionable limits for the advanced stage of disease. Reduced ambulation is located at the PPS 70% and PPS 60% level. This reduction of ambulation is tied to the patient’s inability to carry out their normal job, work occupation, or some hobbies or housework activities. The patients with PPS 70% is still able to walk and transfer on their own. Intake is normal or reduced. We included these patients (PPS = 70) because they may have burden symptoms and may need palliative care support. The second reason is that often symptom of many PND is mental decline and the patients need palliative consultation early. Despite the stated limitations, the study produced useful results, confirming the efficiency of neuropalliative care.

**Conclusion**

Providing palliative care to patients with PND in the form of consultations with a multidisciplinary palliative team may help patients and their family caregivers maintain, and possibly improve, evaluation of quality of life of patients and their family caregivers. For further research,
we recommend analysis of the benefits of different forms of general and palliative care for patients with PND on a larger sample of respondents, and that a long-term study be conducted to determine the connection between palliative intervention and survival. We believe it would be worthwhile to educate doctors (particularly neurologists) and, possibly, other healthcare workers, about the possible utility of palliative care in neurology.

Abbreviations
ADL: Activities of Daily Living; EDSS: Expanded Disability Status scale QoL – quality of life; EFNS: European Federation of Neurological Societies; MND: Motor neuron disease; MS: Multiple sclerosis; PD: Parkinson’s disease; PNDQoL: Progressive Neurological Diseases Quality of Life; PND: Progressive neurological disease; PPS: Palliative Performance Scale

Acknowledgements
This study forms part of the national research project: “A neuropalliative rehabilitative approach to preserving the quality of life in patients with an advanced stage of selected neurological diseases”, supported by the Ministry of Health of the Czech Republic. We would like to thank all contributors and collectors of data - Pavel Ressner, Petra Bártová, Monika Šťastová, Jana Horáková, and Jarmila Sverdlová - and Milada Sovadlová, for language correction.

Authors’ contributions
R.B. was the principal investigator in this research project. R. B and R.K. analyzed the data and interpreted the results, together with M.B. R.B. drafted the manuscript, and all authors read and approved the final manuscript.

Funding
This work was supported by the Ministry of Health of the Czech Republic [grant numbers 17-29447A]. The funder did not participate in the design of the study design, data collection, analysis and interpretation and manuscript preparation.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the appropriate author on reasonable request.

Ethics approval and consent to participate
The study was conducted in accordance with the 1975 Helsinki declaration (and its revisions of 2004 and 2008). Approval was obtained from the ethics committee of University Hospital, Ostrava (10. 6. 2016, no. 486/2016). All patients and family caregivers provided their informed consent prior to their participation. Approval was obtained from the ethics committee of University Hospital Ostrava, Ostrava, Czech Republic.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflict of interests.

Author details
1Department of Nursing and Midwifery, Faculty of Medicine, University of Ostrava, Syllabova 19, 700 30 Ostrava, Czech Republic. 2Neurology clinic, The University Hospital Ostrava Ostrava, Ostrava, Czech Republic.

Received: 7 May 2020 Accepted: 9 September 2020
Published online: 16 September 2020

References
1.  Voltz R, Bernat JL, Borasio GD, Maddocks I, Oliver D, Portenoy RK. Palliative care in neurology. NY: Oxford University Press; 2007.
2.  Sutton L. Addressing palliative and end-of-life care needs in neurology. Br J Neurosci Nurs. 2008;4(5):235–8.
3.  Heegul N, Gao W, Evans CJ, Jackson D, van Vliet LM, Byrne A, et al. Integrating palliative care into neurology services: what do the professionals say? BMJ Support Palliat Care. 2018;8:841–4.
4.  van Vliet M, Gao W, Di Francesco D. How integrated are neurology and palliative care services? Results of a multicentre mapping exercise. BMC Neurol. 2016;16(10):63.
5.  Boesma I, Miyasaki J, Kruiter J, Kluger B. Palliative care in neurology. Time for a paradigm shift. Neurology. 2014;83(5):561–7.
6.  Oliver DJ, Borasio GD, Caraceni AA. Consensus review on the development of palliative care for patients with chronic and progressive neurological disease. Eur J Neurol. 2016;23(1):30–8.
7.  Veigh M, Donaghy C, McLaughlin B, Dick A, Kaur K, Mc Conville J, et al. Palliative care for patients with motor neuron disease and their bereaved carers: a qualitative study. BMC Palliat Care. 2019;18:39.
8.  Bede P, Hardiman O, Borràs-Garnagà D. An integrated Framework of early intervention palliative care in motor neurone disease and as a model to progressive neurodegenerative diseases. Poster at European ALS Congress, Turin, 2009.
9.  Oliver D, Veronese S. Specialist palliative care for Parkinson’s disease. Ann Palliat Med. 2019. https://doi.org/10.21037/apm.2019.12.01.
10. Bede P, Borràs-Garnagà D, Lorenz S, Oliver D, Hardiman O. Symptomatic Management and Palliative Care in Neurodegenerative Disease.
11. Neurodegenerative Disorders. London: Springer; 2011. p. 263–89.
12. Bužgová R, Kozáková R, Bar M, Ressner P, Bartová P. Implementation of a concept of neuropalliative and rehabilitative care for patients with progressive, neurological disease in the Czech Republic qualitative study. In: Thygesen PL, editor. Neurological diseases: from diagnosis to treatment. New York: Nova Science Publisher, Inc.; 2019. p. 73–93.
13. Sepúlveda C, Marlin A, Yoshida T, Ulrich A. Palliative care: the World Health Organization’s global perspective. J Pain Symptom Manag. 2002;24(1):91–5.
14. Kavallieratos D, Corbelli J, Zhang K, Dionne-Odom JD, Emcoff NC, Hamner J, et al. Association between palliative care and patient and caregivers outcomes. A systematic review and meta-analysis. JAMA. 2016;316(20):2104–14.
15. Galvin M, Madden C, Maguire S, Heverin M, Vajda A, Staines A, et al. Patient journey to a specialist amyotrophic lateral sclerosis multidisciplinary clinic: an exploratory study. BMC Health Serv Res. 2015;15:1–8.
16. Andersen PM, Abrahamson S, Borasio GD, De Carvalho M, Chio A, Van Damme P, et al. The EFNS task force on diagnosis and management of amyotrophic lateral sclerosis. EFNS guidelines on the clinical management of ALS - revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360–75.
17. Edmonds P, Hart S, Gao W, Vivat B, Burman R, Silber E, et al. Palliative care for people severely affected by multiple sclerosis: evaluation of a novel palliative care service. Mult Scler. 2010;16(5):367–36.
18. Hasson F, Kernohan WG, McLaughlin M, Waldron M, McLaughlin D, et al. An exploration into the palliative and end-of-life experiences of carers of people with Parkinson disease. Palliat Med. 2010;24(7):731–6.
19. Veronese S, Gallo G, Valle A, Cugno C. Specialist palliative care improves the quality of life in advanced cancer patients. J Pain Symptom Manag. 2012;43(3):503–6.
20. Ringdal GI, Jodhoy MS, Kaasa S. Measuring quality of palliative care: psychometric properties of the FAMCARE scale. Qual Life Res. 2003;12:167–76.
21. Yamagishi A, Morita T, Miyashita M, Igarashi A, Akiyama M, Akaike N. The Pain intensity, quality of life, quality of palliative care, and satisfaction in outpatients with metastatic or recurrent cancer. A Japanese, nationwide, region-based, multicentre survey. J Pain Symptom Manag. 2012;43(3):503–14.
22. Ulrich A, Ascherfeld L, Marx G, Bokemeyer C, Bergelt C, Oechsle K. Quality of life, psychological burden, needs, and satisfaction during specialized inpatient palliative care in family caregivers of advanced cancer patients. BMC Palliat Care. 2017;16(1):1–10.
23. Wentlandt K, Sekcarecchia D, Kevork M, Workentin K, Blacker S, Grossman D, et al. Quality of care and satisfaction with care on palliative care units. Journal of pain and satisfaction with care on palliative care units. J Pain Symptom Manag. 2016;51(2):184–92.
24. Aboshiaq M, Saedi TS, Abu-Al-Ruyahahy MM. Quality of life and satisfaction with care among palliative cancer patients in Saudi Arabia. Palliat Support Care. 2016;14(6):211–7.
25. Aspinal F, Addington-Hall J, Hughes R, Higginson IJ. Using satisfaction to assess the quality of palliative care: a review of the literature. J Adv Nurs. 2003(4):324–39.
26. Thise MS. Observational and interventional study design types, an overview. Biochem Med. 2014;24(2):199–210.
27. Kurtzke JF. Rating neurologic impairment in multiple sclerosis. An expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–52.
28. Cedarbaum JM, Stambler N. Performance of the amyotrophic lateral sclerosis functional rating scale (ALSFRS) in multicenter clinical trials. J Neurol Sci. 1997;152(Suppl1):S1–9.
29. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson’s disease. In: Gillingham FJ, Donaldson IML, editors. Third symposium on Parkinson’s disease. Edinburgh: E. and S. Livingstone; 1969. p. 152–7.
30. Anderson F, Downing GM, Hill J, Casorso L, Lerch N. Palliative performance scale (PPS): a new tool. J Palliat Care. 1996;12(1):5–11.
31. Mahoney FI, Barthel D. Functional evaluation: the Barthel index. Maryland State Med J. 1965;14:56–61.
32. Bužgová R, Kozáková R. Dotazníky pro hodnocení kvality života pacientů s progresivním neurologickým onemocněním a jejich rodinných příslušníků. Manuál pro uživatele dotazníků. Ostrava: Lékařská fakulta Ostravská univerzita; 2020.
33. Heyland DK, Jiang X, Day AG, Cohen SR, CSRENET. The development and validation of shorter version of the Canadian health care evaluation project questionnaire (CANHELP lite): a novel tool to measure patient and family satisfaction with end-of-life care. J Pain Symptom Manag. 2013;46(2):289–97.
34. Dallara A, Tolchin D. Emerging subspecialties in neurology: palliative care. Neurology. 2014;82(18):640–2.
35. Biskop M. Quality of life and psychosocial adaptation to chronic illness and acquired disability: a conceptual and theoretical synthesis. J Rehabilitation. 2005;71:5–13.
36. Hamplová D. Religion and gender: why are women more religious than men? Czech Soc Rev. 2011;47(2):297–323.
37. Steinhauser KE, Fitchett G, Handzo GF, Johnson KS, Koenig HG, Pargament KI, et al. State of the science of spirituality and palliative care research part I: definitions, measurement, and outcomes. J Pain Symptom Manag. 2017;54(3):428–46.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.